Abstract:Blocking inflammatory pathways, e.g. the inflammasome or interleukin (IL)-1β, is a promising therapeutic approach in heart failure (HF). We hypothesized that IL-1β may stimulate cardiac lymphangiogenesis in response to left ventricular (LV) dilation following pressure-overload. Consequently, blocking IL-1β may reduce lymphangiogenesis, delaying resolution of myocardial edema and inflammation, aggravating cardiac fibrosis, and accelerating HF development. Here we investigated the effects of anti-IL-1β treatment during HF development following pressure-overload, induced by transaortic constriction (TAC) in BALB/c mice prone to LV dilation. We examined the molecular mechanisms of IL-1β in macrophages and lymphatic endothelial cells, and assessed links between perivascular fibrosis and lymphatics in HF patients with ischemic or dilated cardiomyopathy (DCM). We found that early anti-IL-1β treatment transiently delayed LV dilation, but did not alter cardiac lymphangiogenesis, hypertrophy, or dysfunction at 8 weeks post-TAC. In contrast, late anti-IL-1β treatment reduced cardiac lymphangiogenesis in response to LV dilation. This was linked to a cell non-autonomous role of IL-1β in promoting cardiac lymphangiogenesis through stimulation of macrophage production and maturation of VEGF-C. Surprisingly, despite reduced lymphatic density in late anti-IL-1β-treated mice, cardiac inflammation, interstitial fibrosis, and dysfunction were not aggravated. Further, we found that perivascular lymphatic density, unaltered by IL-1β, was negatively associated with perivascular fibrosis in HF patients and our TAC model. In conclusion, IL-1β blockage elicited transient functional cardiac benefit when initiated before onset of LV dilation post-TAC in mice. In contrast, late treatment reduced cardiac lymphangiogenesis, but did not significantly accelerate HF development, likely reflecting lymphatic transport dysfunction post-TAC. Our data suggest that the therapeutic window for anti-IL-1β treatment is crucial, as initiation of treatment during the lymphangiogenic response, induced by LV dilation, may diminish the potential cardiac benefit in HF patients. Finally, our data indicate that IL-1β-independent perivascular lymphangiogenesis may limit perivascular fibrosis.

Lentivirus Mediated Il-17r Blockade Improves Diastolic Cardiac Function in Spontaneously Hypertensive Rats

Effect of farnesyltransferase inhibition on cardiac remodeling in spontaneously hypertensive rats

Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats.

Prevention of myocardial fibrosis by using nitrendipine to the spontaneously hypertensive rats

IL-17 Induces Myocardial Fibrosis and Enhances RANKL/OPG and MMP/TIMP Signaling in Isoproterenol-Induced Heart Failure.

The Anti-Inflammatory Mediator 17(R)-Resolvin D1 Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis

Alteration of RhoA Prenylation Ameliorates Cardiac and Vascular Remodeling in Spontaneously Hypertensive Rats.

GW24-e2448 Knockdown of Farnesyl Pyrophosphate Synthase Prevents Cardiac Fibrosis of Spontaneously Hypertensive Ratsin Vivo

The role of IL-17 family cytokines in cardiac fibrosis

Blockage of UCHL1 activity attenuates cardiac remodeling in spontaneously hypertensive rats

Short-Chain Acyl-CoA Dehydrogenase as a Therapeutic Target for Cardiac Fibrosis

Low‐intensity Pulsed Ultrasound Ameliorates Angiotension Ii-induced Cardiac Fibrosisbyalleviating Inflammation via a Caveolin-1-dependent Pathway

In vivo delivery of adenoviral vector containing interleukin-17 receptor a reduces cardiac remodeling and improves myocardial function in viral myocarditis leading to dilated cardiomyopathy.

Brain Interleukin-17A contributes to neuroinflammation and cardiac dysfunction in rats with myocardial infarction

LTBP2 Knockdown Ameliorates Cardiac Fibrosis and Apoptosis via Attenuating NF‐κB Signaling Pathway and Oxidative Stress in Mice with Cardiac Hypertrophy

Leukocyte Ig-like receptor B4 (Lilrb4a) alleviates cardiac dysfunction and isoproterenol-induced arrhythmogenic remodeling associated with cardiac fibrosis and inflammation

Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension

Blocking Interleukin-1β transiently limits left ventricular dilation and reduces cardiac lymphangiogenesis in a mouse pressure-overload model

β-arrestin2 Mediates the Arginine Vasopressin-Induced Expression of IL-1β in Murine Hearts

Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/β-Catenin Signaling Pathway

Calcium-sensing receptor-mediated macrophage polarization improves myocardial remodeling in spontaneously hypertensive rats